A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS (AMBALS)
AMBroxol Therapy for ALS (AMBALS) Trial: a Double-blind, Randomised, Placebo-controlled Phase 2 Clinical Trial of Ambroxol for ALS
Sponsor: Mobius Medical Pty Ltd.
Listed as NCT05959850, this PHASE2 trial focuses on Amyotrophic Lateral Sclerosis and remains ongoing. Sponsored by Mobius Medical Pty Ltd., it has been updated 5 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Aug 2025 — Present [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Aug 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Oct 2023 [monthly]
Recruiting PHASE2
First recorded
Jun 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mobius Medical Pty Ltd.
- The Florey Institute of Neuroscience and Mental Health
- The University of Queensland
For direct contact, visit the study record on ClinicalTrials.gov .